{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:36:29Z","timestamp":1792805789579,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to evaluate the comprehensive safety profile of CDK4\/6 inhibitors in breast cancer treatment by analyzing real-world adverse event (AE) data and systematically reviewing clinical trial findings to provide evidence-based safety guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A disproportionality analysis based on real-world data from the FDA adverse event reporting system (FAERS) was combined with a systematic review to evaluate adverse events (AEs) associated with CDK4\/6 inhibitors. A total of 16 studies involving 6,722 patients with advanced breast cancer were included to analyze the toxicity risks of CDK4\/6 inhibitor combination therapies. Temporal patterns of AEs were assessed using FAERS data, and signal strengths were determined using the reporting odds ratio (ROR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Combination therapy with CDK4\/6 inhibitors significantly increased the risk of grade 3\u20135 AEs. FAERS analysis revealed that most AEs occurred within the first month of treatment, with the lowest incidence between the second and sixth months, followed by a significant rise thereafter. All CDK4\/6 inhibitors were associated with myelosuppression, gastrointestinal toxicity, interstitial lung disease (ILD), and QT prolongation. Disproportionality analysis for \u201cTorsade de pointes\/QT prolongation\u201d identified Ribociclib as the only agent with a strong positive signal (ROR 6.16, 95% CI 5.54\u20136.84). Additionally, unexpected AEs such as peripheral neuropathy, taste disorders, and epistaxis were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinicians should prioritize monitoring for myelosuppression, gastrointestinal toxicity, and QT prolongation (particularly with Ribociclib) during the first month of CDK4\/6 inhibitor therapy. Long-term surveillance beyond 6 months is crucial to detect delayed-onset AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1673284","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:19:28Z","timestamp":1765430368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Toxicity profiles of cyclin-dependent kinase 4\/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Jin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mumu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: Decade report (2005-2015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0121","article-title":"Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies","volume":"23","author":"Murphy","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line Palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+\/HER2- ABC): Analyses from PALOMA-2","volume":"40","author":"Finn","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.34629","article-title":"Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants were analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database","volume":"16","author":"Shimada","year":"2019","journal-title":"Int J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1758835920963925","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.012","article-title":"Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor\u2013positive\/human epidermal growth factor receptor 2 negative advanced breast cancer: Primary results from PALOMA-4","volume":"175","author":"Xu","year":"2022","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-022-06662-9","article-title":"nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2\u2013 metastatic breast cancer","volume":"195","author":"Hamilton","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2021.11.010","article-title":"Randomized phase II study of fulvestrant plus Palbociclib or placebo in endocrine-sensitive, hormone receptor-positive\/HER2\u2013advanced breast cancer: GEICAM\/2014\u201312 (FLIPPER)","volume":"161","author":"Albanell","year":"2022","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","article-title":"Overall survival with Palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study","volume":"168","author":"Mart\u00edn","year":"2022","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/oncolo\/oyac205","article-title":"Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive\/HER2-negative advanced breast cancer: A detailed safety analysis of the randomized PARSIFAL trial","volume":"28","author":"Di Cosimo","year":"2023","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103575","DOI":"10.1016\/j.breast.2023.08.007","article-title":"Anti-hormonal maintenance treatment with the CDK4\/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive \/ HER2-negative metastatic breast cancer: A phase II trial (AMICA)","volume":"72","author":"Decker","year":"2023","journal-title":"Breast"},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-23-1209","article-title":"Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR\u00fe, HER2\u00fe Metastatic Breast Cancer Patients","volume":"30","author":"Tolaney","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-019-05133-y","article-title":"Comparative efficacy of Palbociclib, ribociclib, and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials","volume":"174","author":"Petrelli","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-023-11322-2","article-title":"Comparative efficacy and safety of different combinations of three CDK4\/6 inhibitors with endocrine therapies in HR+\/HER-2\u2009-\u2009metastatic or advanced breast cancer patients: a network meta-analysis","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.10.023","article-title":"Safety of CDK4\/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer","volume":"177","author":"Visani","year":"2022","journal-title":"Radiother Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1758835918793326","DOI":"10.1177\/1758835918793326","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer","volume":"10","author":"Thill","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170330120452","article-title":"HR+, HER2- advanced breast cancer and CDK4\/6 inhibitors: mode of action, clinical activity, and safety profiles","volume":"17","author":"Sammons","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081758","article-title":"Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA adverse event reporting system","volume":"13","author":"Raschi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1981856","article-title":"Association between cyclin-dependent kinase 4\/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data","volume":"21","author":"Yan","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34367","article-title":"Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer","volume":"128","author":"Watson","year":"2022","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06001-w","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment","volume":"186","author":"Raschi","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00129.2009","article-title":"Estrogen-dependent facilitation of spinal reflex potentiation involves the Cdk5\/ERK1\/2\/NR2B cascade in anesthetized rats","volume":"297","author":"Peng","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"B40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.21873\/invivo.12765","article-title":"A comparative safety analysis of medicines based on the UK pharmacovigilance and general practice prescribing data in England","volume":"36","author":"Mokbel","year":"2022","journal-title":"In Vivo"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1673284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:19:29Z","timestamp":1765430369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1673284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1673284"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1673284","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"1673284"}}